Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Promising pre-clinical results support advance to clinical study for third
combination chemotherapy from Celator based on the company's proprietary CombiPlex(TM) technology platform.
PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today
announced positive re...
Determining the Signal-to-Noise Ratio and Optimal Photomultiplier gain setting in the GenePix 4000B
Siobhan Pickett, M.S., Sean Carriedo, Ph.D. and Chang Wang, Ph.D.
Axon Instruments, Inc. 3280 Whipple Road, Union City, CA 94587
Last updated: September 13, 2001
Introduction
An important criterion for comparing the perf...
OncoGenex Reports Second Quarter 2009 Financial Results
...9 months for patients treated with docetaxel alone -- a 6.9
month observed survival advantage for the OGX-011 arm. The unadjusted
hazard
ratio (HR), a measure used to compare the death rates between
treatment groups, was 0.61, representing a 39% lower rate of death for
patients ...
Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
...hed in Cell Stem Cell suggests that reducing the
ratio of these cells within tumors may dramatically impr...hemotherapeutic agents significantly decreases the
ratio of cancer stem cells found in colon and breast tum...hemotherapy alone was demonstrated to increase the
ratio of tumorigenic stem cells found in colon and breas...
Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
...e formulated into small (0.3 micron), neutral liposomes that enable penetration of the biofilm and are highly efficient, with a very low lipid-to-drug
ratio (0.65). ARIKACE can be delivered through nebulization, which enables the small aerosol droplet size (1 to 5 microns) to facilitate more effective d...
Sanofi-aventis Announces Second Quarter 2009 Results
... 13.6%, or of 7.0% at constant exchange rates. The
ratio of cost of sales to net sales improved by 1.2 poin...onstant exchange rates, to euro 1,895 million. The
ratio of selling and general expenses to net sales fell ... At constant exchange rates, growth was 16.0%. The
ratio of operating income - current to net sales improve...
Zimmer Launches New Medical Education and BioSkills Training Program
...dividual surgeon's experience level, providing in-depth knowledge on products and procedures. Zimmer Institute courses have a high faculty-to-student
ratio and incorporate new technologies, promoting greater interaction with faculty trainers and participant collaboration. Courses are offered at many regio...
Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.
...debt and return $60 million to shareholders through share repurchases and a 12% increase in the 2009 quarterly dividend. The Company's debt to capital
ratio was reduced to 28.6% at June 30, 2009 from 34.6% at December 31, 2008. The Company has not experienced any problem in placing its short-term debt in ...
Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males
...1 in 4 pre-teen cases of anorexia are male. There are thousands of males with eating disorders in our society. Historically, it was thought that the
ratio of boys to girls with eating disorders was 1:10, but more recent research indicates that it may be closer to 1:3.
"Over the past 10 years, the ma...
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
...SURE
The ENSURE trial is a multinational (Europe/Asia), double-blind, randomized trial; 396 patients weighing 60 kg or less were randomized in a 2:1
ratio to treatment with either a single dose of 100 mcg corifollitropin alfa or daily 150 IU rFSH (follitropin beta) followed by daily follitropin beta (max...
Stanford researchers find a quicker, cheaper way to sort isotopes
...e chemistry department. The tool can calculate the
ratio of isotopes in a sample by simply "counting the co...l now, the analysis has been done using an isotope
ratio mass spectrometer, which works by giving individua...be used with minimal training.
Existing isotope
ratio mass spectrometers can weigh as much as 1500 pound...
Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36%, Sales Increase 16%
...rrowings and capital lease obligations were $6.1 million at year-end, as compared to $5.0 million at the end of the prior year, and the debt-to-equity
ratio was .23-to-1 at year-end, as compared to .19-to-1 at the end of the prior year.
"This past year was a rewarding, yet challenging year," said Will...
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
....9 months for patients treated with docetaxel alone -- a 6.9 month observed survival advantage for the OGX-011 arm. Furthermore, the unadjusted hazard
ratio (HR), a measure used to compare the death rates between treatment groups, was 0.61, representing a 39% lower rate of death for patients treated with O...
Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
...ery four weeks plus daily ribavirin in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C. 391 patients were randomized in a 4:4:4:3
ratio into four treatment groups, including three that will receive albinterferon alfa-2b administered once every four weeks (900 mcg, 1200 mcg or 1500 mcg)...
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
...to brain tumors while minimizing radiation exposure to healthy organs, including the thyroid, are very encouraging," said Dr. Shen. "With a mean dose
ratio showing 300-fold greater delivery of radiation to the tumor as compared to other organs, Cotara represents a potentially valuable new therapy for GBM ...
Carbon Design Innovations, Inc. Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy, CNT-Probes Deliver New Level of AFM Imaging Performance
...l investment in new instrumentation.
The CCHAR probe offers high-aspect
ratio imaging capability and is designed for materials science, metrology and lif...e science applications. It offers stability and durability in a high-aspect
ratio probe designed for difficult to resolve scanning operations such as deep-tr...
Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
...ive control (phenelzine) and a comparator drug (selegiline). The study results were based on the Tyramine Sensitivity Factor (TSF), which measures the
ratio of tyramine pressor dose before (baseline) and after MAO inhibitor administration. Geometric mean TSFs of all doses of rasagiline were substantially l...
Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C
...opulation with chronic HCV infection, and to compare it with two indices that employ nonspecific biomarkers, aspartate aminotranaminase (AST)-platelet
ratio index (APRI) and Fibrosis-4 (FIB-4). Three hundred and ninety one patients with chronic HCV infection undergoing liver biopsy were enrolled from the L...
Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
...omal encapsulation maintains the desired 5:1 molar
ratio of cytarabine:daunorubicin in CPX-351, extends bio...firmed that CPX-351 maintained the fixed 5:1 molar
ratio of cytarabine:daunorubicin for prolonged periods o... allowing the release of the synergistic 5:1 molar
ratio of the active agents intracellularly, and demonstr...
PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
... cancer, patients in the
PROSTVAC(TM) group had a significantly longer median overall survival by 8.5
months compared to the control group. The hazard
ratio estimate for overall
survival from the study is 0.56 (95% CI 0.37-0.85).
The statistical significance in the final data set is (p=0.006).
...
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
...nt improvement in PFS, was not met, the docetaxel plus AT-101 arm demonstrated a positive trend in OS, as reflected in the Kaplan-Meier curves (hazard
ratio 0.82). This group also demonstrated a 33 percent increase in median survival and a 34 percent increase in 6-month survival compared to the docetaxel ...
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
... survival advantage for the OGX-011 arm.
2) The unadjusted hazard
ratio (HR), a measure used to compare the death
rates between treatment g... is a clear separation of the survival curves," said Blumenstein. "A hazard
ratio of 0.61 indicates a distinct difference in survival rates and fully justifi...
AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
...fer protein (CETP). By transferring
cholesteryl ester from HDLc to LDLc and VLDLc, this protein reduces "good"
HDL and has a detrimental impact on the
ratio of LDLc to HDLc. In the future,
our vaccine will reduce the activity of this protein and shift the balance of
HDLc and LDLc in the blood back in favou...
SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System
...es. For CABG patients, the primary endpoint is the
ratio of obstructed/occluded grafts (defined here as (gr...r CABG patients, the overall obstruction/occlusion
ratio at 15 months was 16 percent, with six percent of g... On a per patient basis, the obstruction/occlusion
ratio was 27 percent, with nine percent of patients havi...
China Biologic Products Announces Strong First Quarter 2009 Results
... Financial Condition
As of March 31, 2009, the Company had $34.0 million in cash, approximately
$2.2 million in working capital and a current
ratio of 1.0. Shareholder's
equity at the end of the first quarter of 2009 was $39.9 million, compared to
$37.2 million at the end of 2008. The Company gen...
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
...ith OGX-011 plus docetaxel in a randomized Phase 2 trial was 27.5 months compared to 16.9 months for patients treated with docetaxel alone. The hazard
ratio (HR), a measure used to determine the difference in survival between treatment groups, was 0.60, representing a 40% reduction in the rate of death for...
ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program
...aceutical customers create better, safer drugs. The 2006 grant added four additional jobs for each job it provided. We expect to greatly increase this
ratio and the total number of new jobs in the next three years."
About ChanTest - The Ion Channel/GPCR Company ( www.chantest.com )
The le...
Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer
...Agency. The study is 90 percent powered to show a 33 percent reduction in risk in overall survival for the treatment arm compared to BSC alone (hazard
ratio = 0.67) (p < 0.05). Our Phase 2 study in resistant or refractory disease or patients who relapsed within 180 days of first-line platinum therapy, d...
Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
...vious record high).
"On the commercial front, adjusted net orders in the first quarter were $589 million, representing an adjusted book-to-bill
ratio of 1.34 to 1. Central laboratory and clinical development services each delivered record adjusted net orders in the quarter, leading to a trailing twe...
PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
...
- Diluted earnings per share of $0.25
- Net quarterly book-to-bill
ratio equates to 1.25
BOSTON, April 27 /PRNewswire-FirstCall/ -- PAREXEL Int... impact from foreign exchange rates of $37.4 million. The net book-to-bill
ratio was 1.25 in the quarter (defined as gross new business less cancellations d...
China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results
...portunity, while
creating further value for our shareholders," concluded Mr. Liu.
Balance Sheet and Cash Flow
The Company had a current
ratio of 1.8 to 1 and $0.6 million in cash and
cash equivalents on December 31, 2008. Stockholders' equity was $13.6 million,
with working capital of $10.2 ...
Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations
...ichment demonstrated to date varies from 3 to 100-fold, which will contribute to Transgenomic's target of achieving a 1/10,000 mutant to normal allele
ratio detection in a routine, cost-effective and high throughput protocol. This level of detection will allow straightforward tumor analysis via surrogate t...
China Biologic Products Announces Strong 2008 Results
... Financial Condition
As of December 31, 2008, the Company had $8.8 million in cash,
approximately $6.3 million in working capital and a current
ratio of 1.3.
Shareholder's equity at 2008 year-end was $37.8 million, compared to $22.4
million at the end of 2007. The Company generated $20.0 million in ...
Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture
... the nonwoven product for different applications. The polymer allows the benefit of altering properties such as the shape of the nonwoven, core sheath
ratio and the weight and structure of the nonwovens. The polymer is also highly compatible with polypropylene. This is of value particularly during the maki...
MIT: 'Alarming' use of energy in modern manufacturing methods
...he inherent inefficiency of current solar panel manufacturing methods could drastically reduce the technology's lifecycle energy balance that is, the
ratio of the energy the panel would produce over its useful lifetime to the energy required to manufacture it.
The new study is just "the first step in d...
China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
...d in October 2008), compared to
$1.4 million on December 31, 2007. The Company had working capital of $67.5
million on December 31, 2008 and a current
ratio of 7.3 to 1. Inventories were
$22.3 million and the accounts receivable balance was $8.2 million on December
31, 2008, compared to $12.0 and $0.3 mill...
Extraordinary General Meetings Statement -- XTL Also Announces Board and Management Changes
...of the shareholders, the Company will take the necessary steps to implement and effect the reverse split, increase in registered share capital and the
ratio change of the Company's ADRs.
David Grossman, the Company's CEO, commented, "On behalf of XTL's new management and Board, we are very excited to...
Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando
... Cardio-diagnostic company adds new apoAI measurement and apoB/apoAI
ratio to advanced lipid profile for heart disease risk stratification
BIRMIN...cluding INTERHEART and the AMORIS trials, have clearly shown the apoB/apoAI
ratio to be superior to all other cardiovascular disease risk marker ratios.
...
Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
... ApoAI and apoB/apoAI
ratio now available with VAP Cholesterol Test at no addi... Cholesterol Test at no added cost.
"The new
ratio gives physicians and their patients a single, easy...RIS trials, have clearly shown that the apoB/apoAI
ratio is superior to all other cardiovascular disease ri...
ERT Reports Fourth Quarter and Full Year 2008 Results
... very pleased that we could increase our gross margin to 57.3%. We were also pleased with the $45.1 million in new bookings and our gross book-to-bill
ratio of 1.5, both up from the third quarter. As a whole, 2008 was very strong. We recorded record revenues, bookings and backlog. Our 2008 operating inc...